INT186882

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.27
First Reported 2004
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 13.45
Pain Relevance 0.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (RTEL1) helicase activity (RTEL1) DNA binding (RTEL1)
Anatomy Link Frequency
B-cell 4
articular 1
capillary 1
RTEL1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Arthritis 52 98.08 Very High Very High Very High
anesthesia 2 93.92 High High
imagery 21 91.92 High High
alcohol 4 70.68 Quite High
Pain 16 48.72 Quite Low
backache 4 41.76 Quite Low
Inflammation 8 41.36 Quite Low
rheumatoid arthritis 12 33.24 Quite Low
cytokine 18 12.48 Low Low
Antihistamine 5 8.96 Low Low
Disease Link Frequency Relevance Heat
Lymphatic System Cancer 506 100.00 Very High Very High Very High
Hodgkin's Disease 83 100.00 Very High Very High Very High
Cancer 150 99.96 Very High Very High Very High
Leukemia 6 99.66 Very High Very High Very High
Disease 159 99.54 Very High Very High Very High
Toxicity 83 99.52 Very High Very High Very High
Systemic Lupus Erythematosus 27 99.48 Very High Very High Very High
Severe Combined Immunodeficiency 18 98.80 Very High Very High Very High
Arthritis 50 98.08 Very High Very High Very High
Acute Myeloid Leukemia 65 97.08 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
For children younger then 42 weeks, postconceptional age an ABR threshold of 40 dB nHL was considered normal.
Gene_expression (threshold) of nHL
1) Confidence 0.27 Published 2010 Journal Eur Arch Otorhinolaryngol Section Body Doc Link PMC2924505 Disease Relevance 0 Pain Relevance 0.09
Cases were newly diagnosed with NHL during the 3-year period between 1 October 1995 and 30 September 1998 and were identified through a rapid case-ascertainment system coordinated with the NYS Cancer Registry.
Gene_expression (diagnosed) of NHL associated with cancer and hodgkin's disease
2) Confidence 0.17 Published 2004 Journal Environ Health Perspect Section Body Doc Link PMC1247516 Disease Relevance 0.60 Pain Relevance 0
On top of this, a computed tomography (CT) scan of the abdomen revealed regression of the mesenteric NHL-tumor mass after chemotherapy, which means that in the case of any presumed intra-articular localization of NHL, one would expect relapse of joint involvement in the course of chemotherapy instead of progression.
Gene_expression (regression) of NHL in articular associated with cancer, hodgkin's disease and recurrence
3) Confidence 0.10 Published 2007 Journal Clin Rheumatol Section Body Doc Link PMC2262146 Disease Relevance 1.68 Pain Relevance 0.19
However, arthritis is unlikely in this patient as autoimmune manifestation, as it developed during R-CHOP and the NHL responded well to this chemotherapy.
Gene_expression (responded) of NHL associated with hodgkin's disease and arthritis
4) Confidence 0.10 Published 2007 Journal Clin Rheumatol Section Body Doc Link PMC2262146 Disease Relevance 1.65 Pain Relevance 0.21
Evidence of clinical efficacy in indolent and aggressive NHL and in both SLE and pSS suggests that epratuzumab is a promising new therapeutic agent for the treatment of B-cell malignancies and B-cell-implicated autoimmune diseases.



Gene_expression (aggressive) of NHL in B-cell associated with autoimmune disease, lymphatic system cancer and systemic lupus erythematosus
5) Confidence 0.06 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376077 Disease Relevance 0.91 Pain Relevance 0
The injection of MSC delayed the development of the peritoneal tumoral masses of the NHL xenografts, and at necroscopic analysis, tumor specimens developed in the absence or presence of MSC showed significant histological differences, which can be recapitulated as follow: while BJAB- and/or SKW6.4-derived peritoneal masses showed the typical faint capillary network also described in human NHL [27], the presence of MSC promoted a diffuse increase in ?
Gene_expression (xenografts) of NHL in capillary associated with lymphatic system cancer and cancer
6) Confidence 0.04 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2886845 Disease Relevance 1.33 Pain Relevance 0
NHL mouse xenograft models
Gene_expression (models) of NHL associated with lymphatic system cancer
7) Confidence 0.04 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2886845 Disease Relevance 0.44 Pain Relevance 0
In addition, whereas Hodgkin's disease spreads in the nodal groups in a contiguous fashion, in NHL the nodal evolution proceeds randomly; this means that it does not proceed in a contiguous fashion, but is instead unforeseeable (obviously, this aspect has important repercussions on the therapeutic protocol).
Gene_expression (fashion) of NHL associated with disease
8) Confidence 0.04 Published 2011 Journal Head Neck Oncol Section Body Doc Link PMC3022892 Disease Relevance 0.98 Pain Relevance 0
131I-TST is FDA approved for the treatment of relapsed or refractory low grade CD20+ B-cell NHL, including disease refractory to RTX, or transformed NHL.
Gene_expression (transformed) of NHL in B-cell associated with lymphatic system cancer and disease
9) Confidence 0.04 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.96 Pain Relevance 0
The annualized incidence of AML/MDS was 1.6%/year which is similar to that of patients treated with multiple chemotherapy regimens.29 In a study of 76 patients treated with upfront 131I-TST monotherapy for follicular NHL, no patients developed MDS/AML with a median follow-up of 7.93 years.30 Distinguishing the attributable risk of MDS/AML to chemotherapy or 131I-TST is difficult, although it appears that 131I-TST does not significantly increase the risk of leukemia.29

131I-TST in relapsed B-cell NHL

Gene_expression (relapsed) of NHL in B-cell associated with leukemia, lymphatic system cancer, myelodysplastic syndromes and acute myeloid leukemia
10) Confidence 0.04 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 2.14 Pain Relevance 0
MDR for low-grade NHL was 8.2 months and MDR for transformed NHL was 12.1 months.19
Gene_expression (months) of NHL associated with lymphatic system cancer
11) Confidence 0.04 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.87 Pain Relevance 0
MDR for low-grade NHL was 8.2 months and MDR for transformed NHL was 12.1 months.19
Gene_expression (transformed) of NHL associated with lymphatic system cancer
12) Confidence 0.04 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.81 Pain Relevance 0
Since RTX approval for B-cell NHL, RTX therapy is considered standard of care in the frontline management of this disease (National Comprehensive Cancer Network guidelines).
Gene_expression (approval) of NHL in B-cell associated with lymphatic system cancer, cancer and disease
13) Confidence 0.04 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 1.10 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox